GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Digipath Inc (OTCPK:DIGP) » Definitions » ROE %

Digipath (Digipath) ROE % : Negative Equity% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Digipath ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Digipath's annualized net income for the quarter that ended in Dec. 2023 was $0.61 Mil. Digipath's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-1.80 Mil. Therefore, Digipath's annualized ROE % for the quarter that ended in Dec. 2023 was Negative Equity%.

The historical rank and industry rank for Digipath's ROE % or its related term are showing as below:

DIGP' s ROE % Range Over the Past 10 Years
Min: -250.52   Med: -107.21   Max: Negative Equity
Current: Negative Equity

During the past 13 years, Digipath's highest ROE % was Negative Equity%. The lowest was -250.52%. And the median was -107.21%.

DIGP's ROE % is ranked better than
99.54% of 218 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.13 vs DIGP: Negative Equity

Digipath ROE % Historical Data

The historical data trend for Digipath's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Digipath ROE % Chart

Digipath Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -250.52 - - - Negative Equity

Digipath Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - Negative Equity Negative Equity Negative Equity

Competitive Comparison of Digipath's ROE %

For the Diagnostics & Research subindustry, Digipath's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Digipath's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Digipath's ROE % distribution charts can be found below:

* The bar in red indicates where Digipath's ROE % falls into.



Digipath ROE % Calculation

Digipath's annualized ROE % for the fiscal year that ended in Sep. 2023 is calculated as

ROE %=Net Income (A: Sep. 2023 )/( (Total Stockholders Equity (A: Sep. 2022 )+Total Stockholders Equity (A: Sep. 2023 ))/ count )
=0.247/( (-2.409+-1.872)/ 2 )
=0.247/-2.1405
=Negative Equity %

Digipath's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=0.608/( (-1.872+-1.719)/ 2 )
=0.608/-1.7955
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Digipath  (OTCPK:DIGP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=0.608/-1.7955
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.608 / 0)*(0 / 1.465)*(1.465 / -1.7955)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=0.608/-1.7955
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0.608 / -0.564) * (-0.564 / -0.284) * (-0.284 / 0) * (0 / 1.465) * (1.465 / -1.7955)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -1.078 * 1.9859 * N/A % * 0 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Digipath ROE % Related Terms

Thank you for viewing the detailed overview of Digipath's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Digipath (Digipath) Business Description

Traded in Other Exchanges
N/A
Address
6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118
DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.
Executives
A Stone Douglass director 10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank director 19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda officer: Chief Executive Officer 111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann director 1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben director 430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser director 4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer director 287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco director 611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson officer: Chief Financial Officer 3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner director 28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc 10 percent owner 16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin director, officer: President C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee 10 percent owner 3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen director, 10 percent owner, officer: CFO 8908 SPLITARROW DRIVE, AUSTIN TX 78717